April 17- Teva Pharmaceutical Industries Ltd said it settled a patent lawsuit with Pfizer Inc, allowing the Israeli drugmaker to launch a generic version of Pfizer's blockbuster painkiller Celebrex in December.» Read More
Regulators act to require US banks to have stronger capital base to reduce financial threats IMF: World economy gains but faces too-low inflation and capital losses from emerging nations US employers posted more job openings in February, a sign that hiring will pick up EU's top court nixes snooping legislation, strengthens privacy rights Stocks rise for the time in four days; Gilead slumps on pressure over new drug Energy Department forecasts slightly lower gasoline prices for the summer and year GM investing $449 M in 2 Detroit-area plants to build next-generation Volt; more jobs expected Japan pharmaceutical company Takeda penalized over diabetes drug, plans to challenge verdict Comcast makes its case for taking over Time Warner Cable, stresses benefits in gov't filings After spike in deaths, railroads launch campaign to highlight dangers of being near tracks
Eli Lilly and Takeda Pharmaceutical were ordered to pay billions in damages over claims that they concealed cancer risks of its Actos diabetes drug.
*Louisiana jury orders $6 bln damages from Takeda, $3 bln from Eli Lilly. SAN FRANCISCO/ TOKYO, April 8- Takeda Pharmaceutical Co Ltd said it would contest $6 billion in punitive damages imposed by a U.S. federal jury in a case alleging that Japan's largest drugmaker had concealed cancer risks associated with its Actos diabetes drug.
TOKYO— A U.S. jury ordered Japanese drugmaker Takeda Pharmaceutical Co. and its U.S. counterpart, Eli Lilly and Co., to pay $9 billion in punitive damages over a diabetes medicine linked to cancer. The U. S District Court in western Louisiana ordered a $6 billion penalty for Takeda and $3 billion for its business partner and co-defendant Eli Lilly.
TOKYO, April 8- Japanese shares fell 1.4 percent to a two-week low on Tuesday as Takeda Pharmaceutical Co tumbled after a U.S. jury ordered it to pay $6 billion over claims it concealed risks associated with its Actos diabetes drug. During the session, the Bank of Japan stood pat on policy as expected after a two-day policy meeting.
Emilia Falcetti, Analyst, Japan Healthcare Equity Research at Cantor Fitzgerald, says Daiichi Sankyo's decision to sell its controlling stake in Ranbaxy will have a negative impact on its earnings.
LITTLE ROCK, Ark.— Arkansas Attorney General Dustin McDaniel asked the state Supreme Court on Monday to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson& Johnson, saying justices did "significant harm" to the state and broke from 170 years of precedent.
EU's top court nixes legislation allowing law enforcement bulk communication data collection Japan pharmaceutical company Takeda penalized over diabetes drug, plans to challenge verdict Global stocks lackluster after tech tumble; Japan declines on lack of additional stimulus After spike in deaths, railroads launch campaign to highlight dangers of being near tracks Only 2 of 9 midsize SUVs get top rating in insurance industry crash tests for 2014 models With economy ailing, new French prime minister sells his ideas to suspicious fellow Socialists Germany says it salvaged power discounts for electricity-heavy companies, which faced EU probe Chinese approval paves way for $7.3 billion sale of Nokia cellphone unit to Microsoft Samsung's profit falls as smartphones get cheaper, competition heats up in emerging markets Highlighting worsening relations, EU challenges Russia at WTO over pork import ban
April 7- Specialty pharmaceuticals company Mallinckrodt Plc will buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its lucrative drug to treat multiple sclerosis, Acthar Gel.
In order to diversify its business, Ireland's Mallinckrodt is buying California-based Questcor Pharmaceuticals in a deal reaching $5.2 billion.
April 7- Specialty pharmaceuticals company Mallinckrodt Plc will buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its lucrative drug to treat multiple sclerosis, Acthar Gel. This acquisition, Mallinckrodt's second deal in less than two months, highlights its efforts to tap into the fast-growing specialty drugs market.
*Investors to get 0.8 Sun Pharma share per Ranbaxy share.
April 7- Specialty pharmaceuticals company Mallinckrodt Plc agreed to buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel.
GENEVA— Swiss drug maker Roche plans to buy IQuum, Inc., a U.S. company that specializes in molecular diagnostics and sample testing, in a deal worth up to $450 million. Roche said Monday that it will pay $275 million upfront for the privately held IQuum, based in Marlborough, Massachusetts.
MUMBAI, India— India's Sun Pharmaceutical Industries is buying troubled generic drugmaker Ranbaxy Laboratories in a $4 billion deal, the companies said Monday. Shares of Ranbaxy, which is 63- percent owned by Japan's Daiichi Sankyo, were down 4.8 percent on the Bombay Stock Exchange.
*Ranbaxy shareholders to get 0.8 Sun Pharma share for each Ranbaxy share. Ranbaxy, India's No.1 drugmaker by sales and 63.4 percent held by Daiichi Sankyo Co Ltd, is banned from exporting drug ingredients to the United States, while Sun Pharmaceutical's Karkhadi plant is also barred from shipping products by the U.S. Food and Drug Administration.
*GSK says investigating alleged "improper conduct" in Iraq. *Iraq issue follows claims of extensive corruption in China. LONDON, April 6- Drugmaker GlaxoSmithKine, already facing corruption accusations in China, is now investigating allegations of bribery in Iraq, the British company said on Sunday.
MUMBAI, April 7- An Indian drugs regulator is among the first to admit that oversight of the nation's huge pharmaceutical industry can be patchy. G.L. Singhal, chief regulator of northern Haryana state, a drugs manufacturing hub, says he needs double the number of inspectors if he is to properly scrutinise factories there.
The company has a deal with Forest Laboratories for co-creation of a dementia drug, which is pending FDA approval. Ally Financial Inc.- The finance company's offering could make taxpayers whole for a $17.2 billion government bailout during the financial crisis. Ally, known as GMAC Inc. at the time of its bailout, had been the auto lending arm for General Motors.
April 4- Halozyme Therapeutics Inc halted a mid-stage trial testing an advanced version of its flagship drug delivery technology in patients with pancreatic cancer, sending its shares tumbling 32 percent.